Founded on the belief that immunotherapy made from a patient’s own cells will transform cancer treatment, Dendreon is fighting for patients by making the battle against cancer personal. By harnessing the power of the body’s immune system, we help extend the lives of patients battling cancer.

Our flagship product, PROVENGE® (sipuleucel-T), was the first FDA-approved immunotherapy made from a patient’s own immune cells. Since its approval in 2010, nearly 30,000 men with advanced prostate cancer have been prescribed PROVENGE. Today, we continue to push our research forward so that we may help even more patients fight cancer with personalized immunotherapy.

Jan 29, 2026
Full time
Dendreon Denver, CO, USA
Dendreon (NASDAQ: DNDN) is a Seattle based biotechnology company. Its lead product, Provenge (known generically as sipuleucel-T), is an immunotherapy for prostate cancer.
Jan 29, 2026
Full time
Dendreon Denver, CO, USA
Dendreon (NASDAQ: DNDN) is a Seattle based biotechnology company. Its lead product, Provenge (known generically as sipuleucel-T), is an immunotherapy for prostate cancer.
Jan 29, 2026
Full time
Dendreon Seal Beach, CA, USA
Dendreon (NASDAQ: DNDN) is a Seattle based biotechnology company. Its lead product, Provenge (known generically as sipuleucel-T), is an immunotherapy for prostate cancer.
Jan 29, 2026
Full time
Dendreon Seal Beach, CA, USA
Dendreon (NASDAQ: DNDN) is a Seattle based biotechnology company. Its lead product, Provenge (known generically as sipuleucel-T), is an immunotherapy for prostate cancer.